Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 3
2016 1
2017 1
2018 2
2019 2
2021 3
2022 5
2023 4
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J; acelERA Breast Cancer Study Investigators. Martín M, et al. J Clin Oncol. 2024 Jun 20;42(18):2149-2160. doi: 10.1200/JCO.23.01500. Epub 2024 Mar 27. J Clin Oncol. 2024. PMID: 38537155 Free PMC article. Clinical Trial.
Genomic medicine and cancer clinical trial in Thailand.
Thamlikitkul L, Parinyanitikul N, Sriuranpong V. Thamlikitkul L, et al. Among authors: parinyanitikul n. Cancer Biol Med. 2023 Aug 23;21(1):10-5. doi: 10.20892/j.issn.2095-3941.2023.0175. Cancer Biol Med. 2023. PMID: 37615313 Free PMC article. No abstract available.
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.
Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF; DESTINY-Breast11 Trial Investigators. Harbeck N, et al. Ann Oncol. 2025 Oct 18:S0923-7534(25)04968-3. doi: 10.1016/j.annonc.2025.10.019. Online ahead of print. Ann Oncol. 2025. PMID: 41130363 Free article.
Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management.
Park YH, Lee SC, Singer CF, Balmaña J, Dent RA, Tan VK, Mulansari NA, Yusof MM, Que FVF, Lu YS, Parinyanitikul N, Pham CP, Taib NA, Kong SY, Antill Y, Kim HJ. Park YH, et al. Among authors: parinyanitikul n. Front Oncol. 2025 Jun 23;15:1507840. doi: 10.3389/fonc.2025.1507840. eCollection 2025. Front Oncol. 2025. PMID: 40626017 Free PMC article. Review.
Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel.
Schutz FAB, Sirachainan E, Kuppusamy S, Hoa NTT, Dejthevaporn T, Bahadzor B, Toan VQ, Chansriwong P, Alip A, Hue NTM, Parinyanitikul N, Tan AL, Hoang VDK, Tienchaiananda P, Chinchapattanam SND, Garg A. Schutz FAB, et al. Among authors: parinyanitikul n. Ther Adv Med Oncol. 2021 Feb 23;13:1758835920985464. doi: 10.1177/1758835920985464. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33747148 Free PMC article. Review.
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Masuda H, et al. Among authors: parinyanitikul n. JCO Precis Oncol. 2022 Mar;6:e2000368. doi: 10.1200/PO.20.00368. JCO Precis Oncol. 2022. PMID: 35294223 Free PMC article.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Im SA, Gennari A, Park YH, Kim JH, Jiang ZF, Gupta S, Fadjari TH, Tamura K, Mastura MY, Abesamis-Tiambeng MLT, Lim EH, Lin CH, Sookprasert A, Parinyanitikul N, Tseng LM, Lee SC, Caguioa P, Singh M, Naito Y, Hukom RA, Smruti BK, Wang SS, Kim SB, Lee KH, Ahn HK, Peters S, Kim TW, Yoshino T, Pentheroudakis G, Curigliano G, Harbeck N. Im SA, et al. Among authors: parinyanitikul n. ESMO Open. 2023 Jun;8(3):101541. doi: 10.1016/j.esmoop.2023.101541. Epub 2023 May 11. ESMO Open. 2023. PMID: 37178669 Free PMC article.
29 results